Business Context and Reporting Period
This Form 8-K was filed by Recursion Pharmaceuticals, Inc. on March 18, 2022. The company is a Delaware corporation incorporated as an emerging growth company, with its principal executive offices in Salt Lake City, Utah. The report primarily addresses a significant clinical development milestone.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate event rather than financial performance data.
Material Changes and Events
- Clinical Trial Enrollment: On March 18, 2022, the company announced the enrollment of the first patient in its Phase 2 clinical trial.
- Drug Candidate: The trial evaluates REC-994, described as a potentially first-in-class, orally bioavailable small molecule.
- Indication: The treatment target is cerebral cavernous malformation.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the inherent uncertainties of clinical trials. The document serves as a notification of the press release attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the full details of the Phase 2 trial design and endpoints in the attached press release (Exhibit 99.1).
- Confirm the current status of the REC-994 program and any subsequent patient enrollment updates.
- Review the company's most recent 10-K or 10-Q for the latest financial position, cash runway, and debt obligations, as this 8-K does not contain such data.